HOME >> MEDICINE >> NEWS
New Muscular Dystrophy Cooperative Research Centers announced

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute of Child Health and Human Development (NICHD), a part of the National Institutes of Health, have funded three new Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers focusing on this group of genetic muscle-wasting diseases. The late Senator Wellstone was a major champion of muscular dystrophy issues in the Congress.

The center at the University of Pennsylvania, co-directed by the university's H. Lee Sweeney, Ph.D., and Kathryn R. Wagner, M.D., Ph.D., of The Johns Hopkins School of Medicine, will explore new strategies for treating a variety of muscular dystrophies (MD). Two laboratory projects are focused on ways to increase muscle growth, and another on examining compounds that may be able to inhibit enzymes involved in breaking down muscle tissue. Clinical trials will determine the safety and feasibility of a potential drug treatment for Duchenne Muscular Dystrophy (DMD). The core facility--a muscle physiology lab--will analyze MD mouse models. Other sites involved with this center are the University of Florida, Gainesville, and the NINDS Intramural Research Program.

Center scientists at Washington, D.C.'s Children's National Medical Center, under the direction of Eric P. Hoffman, Ph.D., and Diana M. Escolar, M.D., will study biochemical pathways that contribute to DMD. A clinical project aims to identify genetic modifiers of the disease, and two laboratory studies focus on muscle cell damage and muscle growth and remodeling in mice. The center also has a bioinformatics and computing core, as well as a clinical core to help support the Cooperative International Neuromuscular Research Group, an existing consortium of MD clinical investigators. Collaborating with the center is the University of Padova in Italy.

The center at the Univers
'"/>

Contact: Ray Fleming
flemingr@mail.nih.gov
301-496-8190
NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases
4-Nov-2005


Page: 1 2

Related medicine news :

1. Columbia receives up to $15 million from Spinal Muscular Atrophy Foundation
2. Researchers suggest TB screening for all international adoptees
3. Researchers find vitamin B1 deficiency key to vascular problems for diabetic patients
4. Researchers link metal ions to neurodegenerative disease
5. RAND presents first Victor Fuchs Research Award to economists at Carnegie Mellon University
6. Wesley Research Institute study targets pharmacists to help diabetes sufferers
7. Researchers develop criteria to detect bone mass deficiencies in children with chronic diseases
8. Research probes seniors plans for end-of-life care
9. DFG approves 11 new Collaborative Research Centers
10. Research shows survival benefit for leukemia patients treated with arsenic trioxide
11. Researchers call for investigation into links between khat use and psychiatric disorders

Post Your Comments:
(Date:8/31/2015)... ... August 31, 2015 , ... ... at Monmouth, was one of the first doctors in the area to perform ... new approach have been impressive: faster recovery, decreased immediate and long-term pain, and ...
(Date:8/31/2015)... ... ... Docs Presents, Dr. Michael Betsy! Dr. Betsy has been reviewed and approved as an ... from Don Bosco Prep in 1990 and was Class Salutatorian. He earned Varsity letters ... senior year. He was inducted into the National Honor Society as a sophomore, was ...
(Date:8/31/2015)... ... 31, 2015 , ... With the FCPX LUT Soft pack from Pixel Film Studios, editors can ... that contains a mathematical formula for modifying an image. The LUT changes every pixel's color ... LUT files. , FCPX LUT Soft requires Final Cut Pro X 10.2 or newer. ...
(Date:8/31/2015)... ... August 31, 2015 , ... How can healthcare meet the ... costs? , In a commentary for The American Journal of Managed Care ... “clinical efficacy,” which would bind parties together in agreements to intervene at the ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... and digital marketing communications company announced today that it has officially launched a ... President, the new website and brand refresh are more closely aligned with the ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 2Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 4Health News:NJ Top Docs Presents, Dr. Michael Betsy! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 3Health News:Pixel Film Studios, FCPX Plugin Developer, Releases FCPX LUT Soft 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 3Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3
(Date:8/31/2015)... Aug. 31, 2015  Asterias Biotherapeutics, Inc. (NYSE ... emerging field of regenerative medicine, today announced that ... Chicago -based Rush University Medical Center ... of escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) ... complete cervical spinal cord injury (SCI). This represents ...
(Date:8/31/2015)... -- Bionomics Limited (ASX:BNO, ADR:BMICY), a biopharmaceutical company focused ... the treatment of diseases of the central nervous system ... submission has passed review by the US Food and ... 1 clinical trial in patients with metastatic colon cancer ... 31 December 2015. Bionomics, CEO & Managing ...
(Date:8/30/2015)... ANDOVER, Massachusetts y LONDRES, August 30, 2015 ... conectada ofrece una visión holística de l ... de todo el trayecto   ... anunciado hoy el debut europeo de IntelliSpace Cardiovascular ... información que ofrece sofisticadas herramientas para acceder, analizar y ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3
Cached News: